Trial Profile
ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Niacin/laropiprant (Primary)
- Indications Ischaemic heart disorders
- Focus Biomarker; Pharmacodynamics
- Acronyms NILACH
- 14 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 14 Mar 2013 Additional lead trial centres deleted as reported by ClinicalTrials.gov record.
- 18 Sep 2012 New trial record